| BCI Minerals Limited (BCI) ORDINARY FULLY PAID |
Materials |
$1,219 |
Quarterly Activities Report
|
29 Jan 2025 9:10AM |
$0.275 |
$0.415 |
risen by
50.91%
|
|
BCI - Price-sensitive ASX Announcement
Full Release
Key Points
- Total Recordable Injury Frequency Rate improved to 4.4.
- Cash and cash equivalents decreased to $65 million.
- Construction of the salt first phase is over 56% complete.
- Pump commissioning and operations ramped up as planned.
- Financial Close achieved on a $981 million syndicated facility agreement.
- Executed offtake agreements covering 62% of forecast production for the first three years.
- First salt on ship targeted for Q2 FY27.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Galan Lithium Limited (GLN) ORDINARY FULLY PAID |
Materials |
$409 |
Galan's Mineral Resources grow to 9.5 Mt LCE
|
29 Jan 2025 9:10AM |
$0.120 |
$0.355 |
risen by
195.83%
|
|
GLN - Price-sensitive ASX Announcement
Full Release
Key Points
- Galan’s Mineral Resources grow to 9.5 Mt LCE.
- Candelas Mineral Resource increases by more than 150% to 1.6 Mt LCE.
- Hombre Muerto resource position places it among top 10 lithium projects globally.
- Significant upside potential for further growth identified in Candelas.
- Focus on Phase 1 financing and construction of Hombre Muerto West.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| White Cliff Minerals Limited (WCN) ORDINARY FULLY PAID |
Materials |
$49 |
Rae Copper Project Fully Permitted for Drilling
|
29 Jan 2025 9:09AM |
$0.020 |
$0.019 |
fallen by
5%
|
|
WCN - Price-sensitive ASX Announcement
Full Release
Key Points
- Rae Copper Project fully permitted for drilling.
- Maiden drilling campaign planned to commence in March 2025.
- Hulk and Danvers targets will be priority.
- Type B Water Licence issued for an initial period of seven years.
- Drilling activities to follow high-priority targets generated in 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Holista Colltech Limited (HCT) ORDINARY FULLY PAID |
Consumer Staple |
$31 |
Quarterly Activity and Cashflow Report
|
29 Jan 2025 9:09AM |
$0.024 |
$0.083 |
risen by
245.83%
|
|
HCT - Price-sensitive ASX Announcement
Full Release
Key Points
- Financial Recovery and Growth Initiatives include a $461K customer deposit and $220K debt recovery.
- Food Ingredient Division revenue increased from $22K to $313K in Q4 FY24.
- Major order from NanoMalaysia for $163K down payment for newly patented nano collagen.
- Appointment of Mr. Leong Man Loong as Executive Director and Interim CEO.
- Total available funds at the end of the quarter were $1.1 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Alcoa Corporation (AAI) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$4,781 |
Change of Officer's Interest Notice
|
29 Jan 2025 9:09AM |
$56.430 |
$91.220 |
risen by
61.65%
|
|
| Breakthrough Minerals Limited (BTM) ORDINARY FULLY PAID |
Energy |
$12 |
Trading Halt
|
29 Jan 2025 9:09AM |
$0.079 |
$0.170 |
risen by
115.19%
|
|
BTM - Price-sensitive ASX Announcement
Full Release
Key Points
- Breakthrough Minerals Limited requested a trading halt.
- The trading halt is pending an announcement regarding a capital raising.
- The halt will last until 31 January 2025 or until the announcement is released.
- The company is not aware of any other information that should be disclosed.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| WCM Global Growth Limited (WQG) ORDINARY FULLY PAID |
Financials |
$444 |
Weekly NTA 24 January 2025
|
29 Jan 2025 9:09AM |
$1.725 |
$1.950 |
risen by
13.04%
|
|
| Waratah Minerals Limited (WTM) ORDINARY FULLY PAID |
Materials |
$169 |
Quarterly Activities Report - December 2024
|
29 Jan 2025 9:07AM |
$0.150 |
$0.545 |
risen by
263.33%
|
|
WTM - Price-sensitive ASX Announcement
Full Release
Key Points
- Ongoing drilling at the Spur Gold-Copper Project is extending gold zones.
- 4,794m of RC drilling completed this quarter, totaling 11,589m to date.
- Dr. Andrew Stewart appointed as Non-Executive Chairman.
- Naomi Scott appointed as Non-Executive Director.
- Waratah has A$4.2 million in cash as of December 31, 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| CurveBeam AI Limited (CVB) ORDINARY FULLY PAID |
Health Care |
$39 |
Investor Presentation - Q2 FY25 Quarterly Update
|
29 Jan 2025 9:07AM |
$0.110 |
$0.083 |
fallen by
24.55%
|
|
CVB - Price-sensitive ASX Announcement
Full Release
Key Points
- CurveBeam AI received purchase orders for ten devices in Q2 FY25.
- This represents a 150% increase from four devices in Q2 FY24.
- Eight of the orders were for the HiRise™ device, setting a record for the quarter.
- Collaboration with Stryker has expanded into CurveBeam's home market.
- The FDA filing for the BMD SaaS module is estimated to be delayed by six months.
- The company expects additional receipts of A$6 million in H2 FY25.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Nelson Resources Limited (NES) ORDINARY FULLY PAID |
Materials |
$14 |
Quarterly Activities and Cashflow Report
|
29 Jan 2025 9:07AM |
$0.003 |
$0.005 |
risen by
66.67%
|
|
NES - Price-sensitive ASX Announcement
Full Release
Key Points
- Placement of $2.3 million completed.
- Dr. Louis Bucci appointed as Executive Director.
- Continued reviews of Fortnum, Yarri, and Woodline gold projects.
- New target areas identified for exploration.
- On-ground exploration planned for first quarter of 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Waratah Minerals Limited (WTM) ORDINARY FULLY PAID |
Materials |
$169 |
Quarterly Cashflow Report - December 2024
|
29 Jan 2025 9:06AM |
$0.150 |
$0.545 |
risen by
263.33%
|
|
WTM - Price-sensitive ASX Announcement
Full Release
Key Points
- Net cash from operating activities was negative $2,011,000.
- Total cash and cash equivalents at end of quarter were $4,234,000.
- Significant cash expenditures were made on exploration and evaluation.
- Cash inflow from financing activities was $2,314,000.
- The focus remains on advancing projects and managing corporate costs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Morphic Ethical Equities Fund Limited (MEC) ORDINARY FULLY PAID |
Financials |
$37 |
Update - Notification of buy-back - MEC
|
29 Jan 2025 9:05AM |
$1.050 |
$1.180 |
risen by
12.38%
|
|
| Algorae Pharmaceuticals Limited (1AI) ORDINARY FULLY PAID |
Health Care |
$24 |
Quarterly Activities Report /Appendix 4C Cash Flow Statement
|
29 Jan 2025 9:05AM |
$0.007 |
$0.015 |
risen by
107.14%
|
|
1AI - Price-sensitive ASX Announcement
Full Release
Key Points
- AI-168 demonstrated 94% restoration of endothelial cell proliferation in preclinical studies.
- AlgoraeOS generated 24 new oncology drug targets and commenced Version 2.0 development.
- AI-116 outperformed Donepezil Hydrochloride in neuroprotection studies.
- Dr. Sarah Siggins joined the Scientific Advisory Board, enhancing leadership.
- Discontinuation of the OTCQB ADS program reduced fixed costs.
- The Company ended the quarter with $2.4 million in cash.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| CurveBeam AI Limited (CVB) ORDINARY FULLY PAID |
Health Care |
$39 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
29 Jan 2025 9:04AM |
$0.110 |
$0.083 |
fallen by
24.55%
|
|
CVB - Price-sensitive ASX Announcement
Full Release
Key Points
- Received ten purchase orders in Q2 FY25, a 150% increase from the previous year.
- Total receipts from customers were A$2.6m, the highest recorded to date.
- Cash at the end of Q2 was A$8.8m, with additional cash receipts expected.
- Continued validation of the enhanced HiRise™ for robotic systems.
- FDA submission for the BMD module targeted for mid-2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atlantic Lithium Limited (A11) ORDINARY FULLY PAID |
Materials |
$161 |
Final Director's Interest Notice
|
29 Jan 2025 9:03AM |
$0.240 |
$0.215 |
fallen by
10.42%
|
|
| Litchfield Minerals Limited (LMS) ORDINARY FULLY PAID |
Materials |
$27 |
Outstanding Results Unveil Scale and Potential at Oonagalabi
|
29 Jan 2025 9:00AM |
$0.120 |
$0.480 |
risen by
300%
|
|
LMS - Price-sensitive ASX Announcement
Full Release
Key Points
- Exceptional Expansion of Oonagalabi system confirmed with over 3km strike.
- New mineralization discovered extending beyond previous drilling limits.
- High-grade soil and rock chip anomalies reinforce the project's potential.
- Strategic exploration plan for 2025 includes geophysical surveys and targeted drilling.
- Oonagalabi project recognized as a flagship for Litchfield Minerals.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| 5G Networks Limited (5GN) ORDINARY FULLY PAID |
Information Technology |
$36 |
CYB: Supplementary Target's Statement
|
29 Jan 2025 8:59AM |
$0.165 |
$0.135 |
fallen by
18.18%
|
|
5GN - Price-sensitive ASX Announcement
Full Release
Key Points
- AUCyber's board unanimously recommends accepting 5GN's revised offer.
- 5GN's revised offer is $0.135 cash per share, a 22.7% increase.
- The offer represents a premium of 31.7% compared to previous share prices.
- AUCyber's financial viability is uncertain amid declining revenues.
- No superior proposals have emerged despite a thorough sales process.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AUCyber Limited (CYB) ORDINARY FULLY PAID |
Information Technology |
$17 |
Supplementary Target's Statement
|
29 Jan 2025 8:59AM |
$0.145 |
$0.081 |
fallen by
44.14%
|
|
CYB - Price-sensitive ASX Announcement
Full Release
Key Points
- 5GN's revised offer represents a 22.7% increase in bid consideration.
- The offer provides certainty of price at $0.135 cash per share.
- No superior proposal has emerged.
- The financial viability of AUCyber remains uncertain.
- AUCyber's directors intend to accept 5GN's revised offer.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,051 |
Q4 2024 Toll Revenue and Traffic Update
|
29 Jan 2025 8:59AM |
$4.930 |
$4.860 |
fallen by
1.42%
|
|
ALX - Price-sensitive ASX Announcement
Full Release
Key Points
- APRR traffic in Q4 was 2.2% higher than the prior corresponding period.
- Toll revenue for APRR was 6.2% higher in Q4 2024.
- Light vehicle traffic in France increased by 2.5% in Q4.
- Heavy vehicle traffic grew modestly, up 0.4% in Q4.
- Traffic at A79 was 9.6% higher in Q4 compared to the previous year.
- Dulles Greenway traffic increased by 9.2% in Q4 2024.
- Chicago Skyway traffic was 1.7% higher than in the previous corresponding period.
- Warnow Tunnel saw a 13.5% increase in traffic in Q4 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$188 |
ACW December 2024 quarterly activity report & Appendix 4C
|
29 Jan 2025 8:58AM |
$0.027 |
$0.059 |
risen by
118.52%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Actinogen is conducting the XanaMIA phase 2b/3 trial for Alzheimer's disease.
- The trial aims to enroll 220 participants with elevated pTau181 blood biomarker.
- The first US patient was randomized on December 9, 2024.
- Over 300 patients are pre-screened, with approximately 40 randomized and treated.
- Interim results anticipated in Q4 2025 and final results in H2 2026.
- Actinogen reported a closing cash balance of $22.9 million at the end of December 2024.
- R&D expenditure for the quarter was $2.3 million, consistent with the previous quarter.
- The company engaged in regulatory meetings to prepare for future marketing approvals.
- Actinogen aims for commercial readiness with Xanamem for Alzheimer's and major depressive disorder.
- The WHO granted the unique nonproprietary name 'emestedastat' for Xanamem.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Microba Life Sciences Limited (MAP) ORDINARY FULLY PAID |
Health Care |
$46 |
Q2 FY25 Quarterly Investor Presentation & Webinar
|
29 Jan 2025 8:58AM |
$0.315 |
$0.075 |
fallen by
76.19%
|
|
MAP - Price-sensitive ASX Announcement
Full Release
Key Points
- Microba Life Sciences Limited reported a 102% increase in Q2 revenue compared to the previous corresponding period.
- MetaXplore test sales in Australia grew by 195% with 2,560 tests sold.
- The UK market is transitioning to a new growth phase with MetaXplore sales commencing.
- The company is advancing its Inflammatory Bowel Disease therapeutic program to Phase 2.
- Microba is leveraging advanced AI and biostatistics for its therapeutic development platform.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aroa Biosurgery Limited (ARX) ORDINARY FULLY PAID |
Health Care |
$264 |
Investor Presentation
|
29 Jan 2025 8:57AM |
$0.800 |
$0.765 |
fallen by
4.38%
|
|
| Agrimin Limited (AMN) ORDINARY FULLY PAID |
Materials |
$25 |
Quarterly Activities Report
|
29 Jan 2025 8:57AM |
$0.145 |
$0.064 |
fallen by
55.86%
|
|
AMN - Price-sensitive ASX Announcement
Full Release
Key Points
- Mackay Potash Project received Western Australian state environmental approval.
- Completion of stage 4 assessment with the Environmental Protection Authority.
- Wyndham Port granted First Point of Entry Status.
- Mining Lease loan of $6.4 million approved by the Western Australian Cabinet.
- Tenement rents payable in 2025 totalling $0.6 million have been deferred to 2026.
- Agrimin aims to establish the Mackay Potash Project as a leading supplier of Sulphate of Potash.
- The project is expected to create significant employment and economic opportunities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Renergen Limited (RLT) CHESS DEPOSITARY INTERESTS 1:1 |
Energy |
$23 |
Cleansing Announcement
|
29 Jan 2025 8:56AM |
$0.470 |
$0.750 |
risen by
59.57%
|
|
| Sigma Healthcare Limited (SIG) ORDINARY FULLY PAID |
Health Care |
$33,361 |
Trading Halt
|
29 Jan 2025 8:56AM |
$3.030 |
$2.890 |
fallen by
4.62%
|
|
SIG - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading halt requested for Sigma Healthcare Limited.
- Pending announcement related to shareholder and Chemist Warehouse scheme meetings.
- Meetings are critical for the Sigma and Chemist Warehouse merger.
- Halt remains until normal trading resumes on 30 January 2025 or announcement release.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
